Nexalin Technology, Inc.

Overview

Compare with POSITRON CORP, iTonic Holdings Ltd or ENDONOVO THERAPEUTICS, INC., or pick any stock.

• TickerNXL on Nasdaq¹
• IndustryElectromedical & Electrotherapeutic Apparatus¹
• HeadquartersHouston, Texas¹
• Incorporated inDE²
• Business address1776 Yorktown, Suite 550, Houston, Tx 77056²
• Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Nexalin is headquartered, and maintains its base of management and operations, in Houston, Texas. We design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as “Generation 1” or “Gen-1” — that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (the “FDA”) as a Class II device.⁴ From its latest annual report

Corporate structure

Nexalin Technology, Inc. sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Nexalin Technology, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

Our principal executive office is located at 1776 Yorktown, Suite 550, Houston, Texas 77056. Under ASC 842 “Leases”, we have a sub-lease (through IIcom Strategic Inc. controlled and owned by our Chief Executive Officer) totaling approximately 4,000 square feet of office space under an operating lease. Management and supporting staff are located at this location. The initial sub-lease expired in January of 2024. The Company entered into a new sublease for the same parties for additional space, which expired in February 2026, at which time the Company is paying month to month. Pursuant to the sublease, we paid the third-party landlord (not the sub landlord) all direct and indirect rent costs under the primary lease directly for the leased premises. No additional payments are made to the Chief Executive Officer or the entity controlled by him.

We do not own or operate manufacturing facilities for the production of any of our products, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We believe our current premises are sufficient for our needs at this time and for the foreseeable future.

Item 2 of the 10-K filed Mar 25, 2026.⁴

Leadership

Who has led Nexalin Technology, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief financial officerMarilyn Elson Sep 19, 2022 to Oct 5, 2023¹²

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• BEIJING NEXALIN NEUROTECH CO., LTD. China³

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

1. Oct 1, 20268-K Entered a material agreement; Regulation FD disclosure¹⁷
2. Oct 1, 20268-K Other events¹⁸
3. Sep 28, 20268-K Listing notice or transfer¹⁹
4. Sep 2, 20268-K Executive or director change²⁰
5. Aug 27, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure²¹
6. Aug 21, 20268-K Entered a material agreement; New debt or obligation²²
7. Aug 20, 20268-K Entered a material agreement; Unregistered sale of shares²³
8. Aug 17, 20268-K Listing notice or transfer²⁴
9. Aug 11, 20268-K Shareholder vote²⁵
10. Jul 29, 20268-K Entered a material agreement²⁶
11. Jul 27, 20268-K Listing notice or transfer²⁷
12. Jun 17, 20268-K Bylaws or fiscal year changed²⁸

Calendar

Coming up

1. Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($3.90) a share, on Nov 14, 2025.²⁹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

200 filings to the SEC since October 2021: 6 annual reports, 12 quarterly reports, 48 major events, 57 insider forms, 2 large holders, 75 other. The latest 20:

1. Oct 8, 2026S-1/A EDGAR
2. Oct 1, 20268-K EDGAR
3. Oct 1, 20268-K EDGAR
4. Sep 28, 20268-K EDGAR
5. Sep 22, 2026S-8 EDGAR
6. Sep 3, 2026SCHEDULE 13D EDGAR
7. Sep 3, 2026S-1 EDGAR
8. Sep 2, 20268-K EDGAR
9. Aug 27, 20268-K EDGAR
10. Aug 27, 2026SCHEDULE 13G EDGAR
11. Aug 21, 20268-K EDGAR
12. Aug 20, 20268-K EDGAR
13. Aug 20, 2026424B5 EDGAR
14. Aug 17, 20268-K EDGAR
15. Aug 12, 202610-Q EDGAR
16. Aug 11, 20268-K EDGAR
17. Jul 29, 20268-K EDGAR
18. Jul 27, 20268-K EDGAR
19. Jul 10, 2026ARS EDGAR
20. Jul 10, 2026DEF 14A EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 23 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Greenlight Ventures, LLCSCHEDULE 13D, 1 filing Sep 3, 2026³⁰
• Alumni Capital LPSCHEDULE 13G, 1 filing Aug 27, 2026³¹

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

SEC filer profile

How Nexalin Technology, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARNexalin Technology, Inc.¹
• CIK0001527352
• Employer ID (EIN)27-5566468⁴
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address1776 Yorktown, Suite 550, Houston, TX 77056¹
• Phone(832) 260-0222¹
• Shares outstanding22,036,402 as of Aug 10, 2026¹⁰
• Public float$14.7M as of Jun 30, 2025⁴
• AuditorCBIZ CPAs P.C., Marlton, New Jersey PCAOB ID 199⁴
• On EDGAR sinceAug 9, 2011¹
• Filings202 in all: 8-K (47), 4 (39), S-1/A (15), CORRESP (13), UPLOAD (13), 10-Q (12), 3 (7), 4/A (6)¹
  All 33 form types

  DEF 14A (5), 10-K (4), 424B4 (4), EFFECT (4), S-1 (4), 424B5 (3), 5 (3), 10-K/A (2), 3/A (2), DRS (2), DRS/A (2), S-3 (2), 144 (1), 25-NSE (1), 8-A12B (1), 8-K/A (1), ARS (1), CERT (1), D (1), DRSLTR (1), PRE 14A (1), RW (1), S-8 (1), SCHEDULE 13D (1), SCHEDULE 13G (1)

• Latest filingsAnnual report (10-K) Mar 25, 2026
  Quarterly report (10-Q) Aug 12, 2026
  Proxy statement (DEF 14A) Jul 10, 2026
  Latest 8-K (8-K) Oct 1, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 25, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Nexalin Technology, Inc. names in Item 1A of its 10-K filed Mar 25, 2026: 50 risks under these headings, as written.⁴

• Risks Related to Our Financial Position and Capital Needs
• We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.
• We may not be able to continue as a going concern if we do not execute our business plan or obtain additional financing in the future if necessary.
• Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
• We will require additional funding to meet our financial needs and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to delay, reduce or altogether cease our product development programs or commercialization efforts.
• Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or products.
• Risks Related to the Development of Our Products and Preclinical Program
• We depend on the success of our future products, some of which are in clinical development but have not completed advanced clinical trials. If we fail to obtain regulatory approval for and successfully commercialize one or more of our products or if we experience significant delays in doing so, we may never become profitable.
• Our products and product candidates may be subject to reclassification by the FDA, and a change in the classification may have an adverse impact on our revenues or our abilities to obtain necessary regulatory approvals.
• Success in preclinical studies or clinical trials may not be indicative of results in future clinical trials.
• If we experience delays or difficulties in the enrolment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
• Risks Related to Our Dependence on Third Parties

Legal proceedings

From time to time, we may become involved in legal proceedings arising in the ordinary course of business. As of the date of this Report, there are no material pending legal proceedings in which the Company or any of its subsidiaries is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of its voting securities, or security holder is a party adverse to us or has a material interest adverse to the Company other than the following:

Employment Development Department

The Company entered into a settlement discussion with the Employment Development Department (EDD) of the State of California. This matter involved issues related to our previous management’s classification of certain work provided to or on behalf of the Company’s business as contract labor instead of employee labor. The total amount involved was approximately $300,000. Management petitioned for reassessment and believed the workers at issue were indeed actual contractors and not employees. We have no business in California other than one part time and one full time worker residing in California. The EDD approved a significant downward adjustment in our outstanding employment tax liability to approximately $40,000 and later to approximately $30,000. All amounts were paid prior to December 31, 2025 and this matter is settled.

The opening of Item 3, Legal Proceedings.⁴